Definium Therapeutics, Inc. (DFTX) Earnings
Definium Therapeutics, Inc. is expected to report next earnings on July 30, 2026 (in NaN days), with a consensus EPS estimate of $-0.55. DFTX has beaten EPS estimates in 5 of its last 12 reported quarters (average surprise -30.8% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.49 | $-0.71 | -44.3% | — | — |
| Nov 6, 2025 | $-0.52 | $-0.78 | -50.0% | — | — |
| Jul 31, 2025 | $-0.38 | $-0.50 | -31.6% | — | — |
| May 8, 2025 | $-0.36 | $-0.35 | +2.8% | — | — |
| Mar 6, 2025 | $-0.33 | $-0.41 | -24.2% | — | — |
| Nov 7, 2024 | $-0.29 | $-0.27 | +6.9% | — | — |
| Feb 28, 2024 | $-0.48 | $-0.59 | -22.9% | $5M | — |
| Nov 2, 2023 | $-0.65 | $-0.53 | +18.5% | — | — |
| Aug 3, 2023 | $-0.54 | $-0.72 | -33.3% | — | — |
| May 4, 2023 | $-0.41 | $-0.51 | -24.4% | — | — |
| Mar 9, 2023 | $-0.49 | $-0.27 | +44.9% | — | — |
| Nov 10, 2022 | $-0.58 | $-0.56 | +3.4% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Robert Barrow noted 2026 is a pivotal year with advanced late - stage clinical programs, near - term data readouts, and team building. Daniel Karlin updated on clinical programs: DT120 ODT has ongoing Phase III studies in MDD, GAD, and PTSD; EMERGE in MDD has completed enrollment and is on track for topline results later this quarter; VOYAGE and PANORAMA in GAD are near topline data readouts. DT402 in ASD Phase II study is advancing. Matthew Wiley discussed commercial strategy for DT120, targeting high - volume healthcare practitioners and the market opportunity. Brandi L. Roberts presented financial results: Research and development expenses were $41.5 million in Q1 2026 compared to $23.4 million in Q1 2025. General and administrative expenses were $17.7 million in Q1 2026 compared to $8.8 million in Q1 2025. Net loss for Q1 2026 was $77.1 million compared to $23.3 million in Q1 2025. Ended Q1 2026 with $373.4 million in cash, cash equivalents, and investments.
Guidance
Anticipates multiple pivotal data readouts across the second and third quarters for DT120, with a focus on disciplined execution and moving towards potential commercial launch. The company is well - positioned with its financial position to support operations through anticipated clinical readouts into 2028.
Analyst Q&A
Q: Assuming success in MDD and anxiety this year, speak to thoughts on long - term safety and retreatment data needed for approval and long - term exposure for safety.
A: Robert Barrow and Daniel Karlin discussed safety data, Part B of studies, and how it relates to informing FDA and the clinical community.
Q: In terms of patient experience and monitoring, how confident are you that only one dosing session monitor will be needed and thought process behind PTSD HAVEN study design.
A: Daniel Karlin addressed patient monitoring based on FDA direction and the rationale for the PTSD HAVEN study design.
Q: On patient journey, talk about what gets closer to five hours in Phase III vs eight and thoughts on placebo response in GAD and MDD Phase IIIs.
A: Robert Barrow and Daniel Karlin discussed factors in patient journey and placebo response.
Q: About PTSD program, convictions regarding dose and submission in MDD or GAD.
A: Robert Barrow and Daniel Karlin answered on PTSD dose and submission considerations.
Q: Overlap of MDD and GAD, probability of success, and placebo in GAD.
A: Daniel Karlin discussed MDD and GAD overlap, probability of success, and placebo in GAD.
Q: For MDD OLE, reason for redosing trigger at MADRS score of 20 or greater and preparations at clinics for DT120.
A: Daniel Karlin and Matthew Wiley answered on redosing trigger and clinic preparations.
Q: Economic incentives for clinics to modify capacity for DT120 and advantages over Spravato, and PTSD differentiated advantages.
A: Matthew Wiley and Daniel Karlin addressed economic incentives and PTSD advantages.
Q: Filing strategy, which indication more challenging, and real - world advantages/disadvantages of Commissioner’s National Priority Voucher.
A: Robert Barrow and Matthew Wiley discussed filing strategy, challenging indication, and voucher advantages/disadvantages.
Q: EMERGE readout granularity of patient time - to - discharge data and label with eight - hour treatment window.
A: Robert Barrow responded on EMERGE data granularity.
Q: DEA rescheduling time saving and DT402 in ASD metrics.
A: Robert Barrow and Daniel Karlin answered on DEA rescheduling and DT402 metrics.
Q: Data needed from Part B and market capacity for DT120.
A: Robert Barrow addressed data needed from Part B and market capacity.